SEC Form 4 · accession 0001225208-16-037271

Edwards Lifesciences Corp · EW

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CVP, Europe

Period of report

Jul 28, 2016

Accepted (ET)

Aug 1, 2016 · 8:37 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001099800

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jul 28, 2016	M	5,000	$25.48	A	133,952	D
Common Stock^F2	Jul 28, 2016	S	5,000	$115.00	D	128,952	D
Common Stock^F2	Jul 29, 2016	M	5,000	$25.48	A	133,999	D
Common Stock^F3,F2	Jul 29, 2016	S	5,000	$114.7343	D	128,999	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Acquire)^F2	$25.48	Jul 28, 2016	M	5,000	D	May 13, 2011	May 12, 2017	Common Stock	5,000	83,000	D
Employee Stock Option (Right to Acquire)^F2	$25.48	Jul 29, 2016	M	5,000	D	May 13, 2011	May 12, 2017	Common Stock	5,000	78,000	D

F1This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.
F2This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
F3This transaction was executed in multiple trades at prices ranging from $114.7301 to $114.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.